|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
49.50(B) |
Last
Volume: |
1,689,979 |
Avg
Vol: |
1,912,163 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
214,480 |
278,554 |
302,923 |
570,485 |
Total Sell Value |
$28,881,982 |
$36,708,660 |
$39,498,005 |
$69,560,865 |
Total People Sold |
7 |
10 |
14 |
15 |
Total Sell Transactions |
14 |
27 |
46 |
79 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2022-03-04 |
4 |
AS |
$422.94 |
$253,764 |
D/D |
(600) |
14,662 |
|
-82% |
|
Patterson Chad |
EVP, Global Marketing |
|
2022-03-01 |
4 |
AS |
$413.97 |
$19,043 |
D/D |
(46) |
12,528 |
|
-81% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2022-02-23 |
4 |
AS |
$394.33 |
$98,583 |
D/D |
(250) |
34,370 |
|
-79% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2022-02-14 |
4 |
AS |
$418.04 |
$1,254,120 |
D/D |
(3,000) |
94,617 |
|
-81% |
|
Kahn Barbara |
Director |
|
2022-02-10 |
4 |
AS |
$428.55 |
$2,064,014 |
I/I |
(4,666) |
3,000 |
|
-84% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2022-01-24 |
4 |
AS |
$416.77 |
$104,193 |
D/D |
(250) |
34,620 |
|
-27% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2022-01-18 |
4 |
AS |
$435.06 |
$9,875,800 |
D/D |
(22,674) |
97,617 |
|
-35% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
38,586 |
117,291 |
|
- |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-12-23 |
4 |
AS |
$573.91 |
$143,478 |
D/D |
(250) |
34,870 |
|
-29% |
|
Stern Sadie |
EVP Chief Human Resources Off |
|
2021-12-15 |
4 |
A |
$0.00 |
$2 |
D/D |
1,671 |
13,461 |
|
- |
|
Patterson Chad |
EVP, Global Marketing |
|
2021-12-15 |
4 |
A |
$0.00 |
$3 |
D/D |
2,925 |
12,528 |
|
- |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2021-12-15 |
4 |
A |
$0.00 |
$3 |
D/D |
2,925 |
72,247 |
|
- |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2021-12-15 |
4 |
A |
$0.00 |
$3 |
D/D |
2,925 |
15,217 |
|
- |
|
Regan Barry J. |
EVP Operations |
|
2021-12-15 |
4 |
A |
$0.00 |
$2 |
D/D |
1,671 |
13,128 |
|
- |
|
Flynn Paul R |
EVP, Global Revenue |
|
2021-12-15 |
4 |
A |
$0.00 |
$3 |
D/D |
2,925 |
13,853 |
|
- |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2021-12-15 |
4 |
AS |
$528.06 |
$1,607,899 |
D/D |
(3,000) |
81,705 |
|
-24% |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2021-12-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,459 |
35,120 |
|
- |
|
Regan Barry J. |
EVP Operations |
|
2021-12-13 |
4 |
AS |
$563.93 |
$684,611 |
D/D |
(1,214) |
11,457 |
|
-19% |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2021-12-06 |
4 |
AS |
$517.59 |
$310,554 |
D/D |
(600) |
12,292 |
|
-8% |
|
Selvaraj Shelly Ramasamy |
SVP Information Technology |
|
2021-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
250 |
12,764 |
|
- |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2021-11-15 |
4 |
AS |
$644.59 |
$1,943,515 |
D/D |
(3,000) |
84,705 |
|
-20% |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2021-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
87,705 |
|
- |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2021-11-09 |
4 |
A |
$634.12 |
$402,032 |
D/D |
634 |
12,892 |
|
- |
|
Foletta Mark G |
Director |
|
2021-11-01 |
4 |
AS |
$615.13 |
$313,162 |
I/I |
(500) |
13,097 |
|
-34% |
|
Augustinos Nicholas |
Director |
|
2021-10-29 |
4 |
AS |
$600.03 |
$1,500,087 |
D/D |
(2,500) |
918 |
|
-35% |
|
2278 Records found
|
|
Page 10 of 92 |
|
|